Compare AUB & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUB | ORKA |
|---|---|---|
| Founded | 1902 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 7.1B |
| IPO Year | 2005 | 1997 |
| Metric | AUB | ORKA |
|---|---|---|
| Price | $42.56 | $112.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $41.88 | ★ $92.50 |
| AVG Volume (30 Days) | ★ 941.1K | 756.1K |
| Earning Date | 04-21-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.95 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.16 | N/A |
| Revenue Next Year | $4.59 | N/A |
| P/E Ratio | $21.99 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.87 | $14.08 |
| 52 Week High | $43.62 | $111.37 |
| Indicator | AUB | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 55.06 | 75.19 |
| Support Level | $40.74 | $82.34 |
| Resistance Level | $43.58 | N/A |
| Average True Range (ATR) | 0.71 | 5.61 |
| MACD | -0.07 | 1.07 |
| Stochastic Oscillator | 70.01 | 96.74 |
Atlantic Union Bankshares Corp is a financial and bank holding company based in the U.S. Through its community bank subsidiary and non-bank financial services affiliates, the company provides financial services, including banking, trust, and wealth management. It offers consumers and businesses a wide range of banking and related financial services, including checking, savings, certificates of deposit, and other depository services, as well as loans for commercial, industrial, residential mortgage, and consumer purposes. The company operates through two reportable operating segments: Wholesale Banking and Consumer Banking, with corporate support functions such as corporate treasury and others included in Corporate Other. It derives maximum revenue from the Wholesale Banking segment.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.